A recent paper in the New England Journal of Medicine reports on a double-blinded clinical trial that was ended early due to beneficial effects. “Remdesivir for the Treatment of Covid-19 — Preliminary Report” It reports a median time to recovery of 11 days for those treated, as opposed to 15 days for those in the control group. There is a VERY low chance of this being a difference due to chance. The 14-day mortality rates of 7% for the treatment group and 12% for the control group were not statistically significant. If we conclude that Remdesivir has no effect on survival rates based on this non-significant difference (not a conclusion I’d support), then this appears to behave like the hypothetical drug of the previous post on the issues with the Cox Proportional Hazards model. Thankfully, this was not how they analyzed the relevant data.
Disclosure: I know, and have written papers with, people involved with the study.
No comments:
Post a Comment